Market Newsdesk

TEL AVIV, Israel, Nov. 12, 2020 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a leading provider of cyber security and application delivery solutions, today announced the results of its Annual General Meeting of Shareholders held November 10, 2020. The Company presented six proposals for the shareholders to vote on at the meeting. All six proposals voted on at the Annual General Meeting were adopted by the requisite shareholder vote.

About Radware


Radware
® (NASDAQ: RDWR), is a global leader of cyber security and application delivery solutions for physical, cloud, and software defined data centers. Its award-winning solutions portfolio secures the digital experience by providing infrastructure, application, and corporate IT protection and availability services to enterprises globally. Radware’s solutions empower enterprise and carrier customers worldwide to adapt to market challenges quickly, maintain business continuity and achieve maximum productivity while keeping costs down. For more information, please visit www.radware.com.

The contents of any website or hyperlinks mentioned in this press release are for informational purposes and the contents thereof are not part of this press release.

Media Contacts:

Deborah Szajngarten
Radware
201-785-3206
[email protected]

Investor Relations:

Anat Earon-Heilborn
+972 723917548
[email protected]

TORONTO, Nov. 12, 2020 (GLOBE NEWSWIRE) — People are checking their credit reports and scores more frequently and are taking identity theft more seriously as compared to previous years, according to a recent consumer survey conducted by Equifax Canada.

COVID-19 has caused many people to take a closer look at their financial situation, which is resulting in an increased understanding about their relationship with credit. Within the last 12 months, 71 per cent of survey respondents have checked their credit report, including 57 per cent in the last month. Younger adults (under age 55) and Quebecers were significantly more likely to have checked their credit reports on a regular basis. This is a significant shift for consumers when considering 67 per cent of survey respondents ‘rarely or never checked their credit reports’ according to a similar survey conducted by Equifax in 2016.

“The pandemic has clearly impacted everyone so much that more people feel the need to assess their financial situation,” said Rebecca Oakes, Equifax Canada’s AVP of Advanced Analytics. “Checking your credit reports and obtaining credit scores is a good place to start. It’s actually encouraging to see a higher percentage of people checking their credit reports and scores now compared to a few years ago.”

Equifax Canada data indicates that payment deferrals have been utilized with over 3 million consumers taking a payment deferral since the pandemic started. Thus far, 14 per cent of open mortgages have had at least one month of payment deferral (approximately 900,000 deferred mortgages) and two per cent of open credit cards have had at least one month of payment deferral (approximately 1.2 million deferred credit cards). About half of deferred mortgages have had continued deferred payments for the past four months, while credit cards have had a shorter deferral duration of one or two months.

CREDIT SCORES ALSO CHECKED MORE FREQUENTLY

In addition to checking their credit reports, survey respondents indicated they are obtaining their credit scores more frequently. More than half (54 per cent) said they obtain their score at least annually, as compared to 48 per cent a year ago. Younger adults (those aged 18-34) are significantly more likely to check their credit scores monthly versus those over the age of 35 (37 per cent in 2020 vs. 27 per cent in 2019).

“COVID-19 has caused many Canadian households to develop a better understanding of their finances on the fly,” said Keith Emery, Co-CEO of Credit Canada. “Knowing what’s in your credit reports and how credit scores are calculated are important steps towards improved financial wellness. We always caution people to avoid anyone offering to ‘fix’ your credit score. The best road to a healthy credit score is making bill payments on time. It’s as simple as that.”

STEPS TO PREVENTING IDENTITY THEFT

Equifax data collected and analyzed from its consortium of lenders and industry partners also indicates that fraudsters and identity thieves are more active and looking to take advantage of the COVID-19 crisis. Since the pandemic began, the application fraud rate has increased by 43 per cent and the deposit account fraud rate rose by 53 per cent peaking in April and May respectively.

Fortunately, survey results indicate that Canadians continue to take the threat of fraud and identity theft seriously. When comparing survey results to four years ago the numbers are trending in the right direction. More people are taking precautionary steps to help protect against fraud and identity theft.

2020		Steps Taken by Consumers	2016
83%		Review credit card statements on receipt for fraudulent activity	79%
65%		Check my credit report	28%
59%		Avoid using public Wi-Fi	47%
54%		Update security passwords	43%

“Identity thieves and fraudsters are quick to take advantage of any crisis,” said Oakes. “COVID-19 has forced many people to work online from home, buy their groceries online, and in a lot of cases stay socially connected to friends and family online. Spending more time online safely requires making sure you are taking steps to help protect yourself. Checking your credit report regularly remains one of the best ways to recognize and help protect against fraud and identity theft.”

To learn more about fraud prevention and how credit works, consumers are encouraged to visit Equifax Canada’s education hub. The site offers insights on how different actions may affect their credit scores and provides resources to help improve their financial wellness.

_{*An online survey of 1,539 Canadians was completed between September 11-13, 2020, using Leger’s online panel. The margin of error for this study was +/-2.5%, 19 times out of 20.}

About Equifax
At Equifax (NYSE: EFX), we believe knowledge drives progress. As a global data, analytics, and technology company, we play an essential role in the global economy by helping financial institutions, companies, employees, and government agencies make critical decisions with greater confidence. Our unique blend of differentiated data, analytics, and cloud technology drives insights to power decisions to move people forward. Headquartered in Atlanta and supported by more than 11,000 employees worldwide, Equifax operates or has investments in 25 countries in North America, Central and South America, Europe, and the Asia Pacific region. For more information, visit Equifax.ca.

About Credit Canada
Credit Canada is a not-for-profit credit counselling agency providing free and confidential debt and credit counselling, personal debt management, debt consolidation and resolutions, as well as preventative counselling, educational seminars, and free tips and tools in the areas of budgeting, money management, and financial goal-setting. Credit Canada is Canada’s first and longest-standing credit counselling agency and a leader in financial wellness, helping Canadians successfully manage their debt since 1966. Please visit www.creditcanada.com for more information and follow us on Facebook and Twitter.

Media Contact:

Andrew Findlater
SELECT Public Relations
[email protected]
(647) 444-1197

HOUSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) — iland, a leading VMware-based cloud services provider for application hosting, data protection and disaster recovery, today released the findings of its research into customer confidence in cloud services. It found that despite the increase in cloud adoption due to the pandemic, three quarters of organisations surveyed say hyperscaler IaaS instance types may not meet their cost and performance needs for mission-critical applications, while more than one in five are not satisfied with key features of cloud provision such as security, performance, availability and support.

The research also found that a lack of migration resources is delaying or preventing cloud projects for more than 80% of organisations surveyed.

The research: The Hidden Pitfalls of Working with Hyperscale Clouds was conducted among 501 senior IT executives, including CIOs, CISOs and CTOs, in the UK and US by independent research organisation, Opinion Matters, in June 2020. Participants were asked for their views on security, performance, compliance and their overall level of confidence in the cloud services they have invested in.

Key research findings include:

• 83% say lack of migration resources and/or time has delayed cloud migration. Among those, 12% say it has entirely prevented migration.
• 75% say a T Shirt size or hyperscaler instance type does not meet all their performance and cost requirements.
• 24% are not confident that hyperscale clouds can meet performance and availability requirements for specific applications.
• 23% are not confident that production data is protected via backup or disaster recovery in the event of data loss with their cloud service provider.
• 24% are not confident they can get the support they need from their cloud service provider.
• 53% say security is the top factor in cloud supplier selection.
• 76% agree CSPs should assist or actively manage customer data compliance.

Commenting on the research findings, Researcher Charles Moore said: “While cloud adoption has seen a significant uptick due to the pandemic, the lack of migration resources for many customers has delayed or prevented deployment. Customers need to choose a cloud vendor that can fill the internal resource gaps that can hinder success.”

Justin Giardina, iland Chief Technology Officer, added: “The business benefits of moving to the cloud are indisputable, but with 83% of those surveyed saying that migration resources are necessary to achieve those benefits it’s clear that customers need to look beyond just the cloud platform and ensure their vendor can offer the supporting services that can reduce risk and improve time to value.”

“Hyperscale cloud services are missing the mark for a significant proportion of the organisations surveyed,” continues Giardina. “Having trust in critical cloud features is fundamental to realising its benefits, so with more than one in five respondents lacking confidence in aspects such as performance, availability, backup and support points to the hidden pitfalls of hyperscale clouds.”

Security, management, visibility, and control are priority customer requirements for cloud solutions

The study also found that key requirements for cloud service provision include common or unified management across all services; this is a priority for 73% of those adopting multi-cloud solutions. Similarly, infrastructure visibility and control are must-have features for 71% of respondents. Many were looking to the future, with 89% saying it was important or critical that they can write to their CSP’s API for future software development and deployment.

Security is a primary criterion for cloud provider selection, with 53% saying it is the leading consideration and a further 43% saying it is a major factor. Three quarters of customers also want to see cloud service providers helping manage data compliance.

The survey found that the majority (74%) of respondents felt it was important that CSPs preserve their company’s existing networking environment when they move to the cloud. This reflects the current landscape, where many organisations are being forced to accelerate their cloud adoption programmes due to the pressures of supporting large-scale remote working. Giardina notes: “When organisations are being rapidly pushed out of their comfort zones and forced to shrink deployment schedules to the absolute minimum, being able to maintain the familiar networking environment in the cloud is an advantage that is appealing to under-pressure IT departments.”

Read the full iland research report here.

About iland

iland is a global cloud service provider of secure and compliant hosting for infrastructure (IaaS), disaster recovery (DRaaS), and backup as a service (BaaS). They are recognized by industry analysts as a leader in disaster recovery. The award-winning iland Secure Cloud Console natively combines deep layered security, predictive analytics, and compliance to deliver unmatched visibility and ease of management for all of iland’s cloud services. Headquartered in Houston, Texas and London, UK, iland delivers cloud services from its data centers throughout North America, Europe, Australia, and Asia. Learn more at www.iland.com.

James Costanzo
iland
6315535860
[email protected]

FARMINGTON HILLS, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced the publication of two seminal papers supporting its APX3330 program. The first is a review paper on the Ref-1 protein, a novel molecular target involved in multiple inflammatory and angiogenic disease processes, focusing on ocular, gastrointestinal, and cancer disorders in Drug Discovery Today, a journal dedicated to all aspects of preclinical drug discovery. The second publication covers a preclinical study outlining the benefits of APX3330 that were shown in mouse models of chronic colitis, an inflammatory condition, in the peer-reviewed journal Inflammatory Bowel Disease.

The publication entitled, “The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease,” reported the following:

• Ref-1 has emerged as a novel therapeutic target developed for treating ocular diseases
• Findings in other indications, such as in preclinical models of cancer and IBD, support the targeting of Ref-1 to interfere with angiogenesis and inflammation in ocular disease such as diabetic retinopathy (DR), diabetic macular edema (DME), and age-related macular degeneration (AMD) with APX3330, APX2009, and APX2014
• Findings from a solid tumor Phase-1 trial, where doses up to 600 mg per day of APX3330 demonstrated chronic tolerability, for some patients up to a year
• Use of Ref-1 inhibitors has also promoted prevention of neuropathy in preclinical studies

The full online publication can be accessed at the following link: sciencedirect.com

The second publication entitled, “Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis,” reported the following:

• Inflammation-induced oxidative stress is implicated in the pathophysiology of GI dysfunction in IBD

• When given systemically to mice with chronic colitis, APX3330 reduced mitochondrial superoxide production, oxidative DNA damage, leading to neuroprotective effects of the enteric nervous system
• APX3330 improved disease severity, reduced immune cell infiltration, restored GI function, and demonstrated Ref-1 target inhibition

The full online publication can be accessed at the following link: academic.oup.com

Mark Kelley, PhD, member of Ocuphire’s Ocular Medical Advisory Board, commented, “The results presented in both publications support the underlying mechanism of action of Ref-1 inhibitors in the prevention of inflammation and angiogenesis as well as the potential chronic daily use of APX3330 for ocular diseases.”

These publications offer evidence on the anti-inflammatory and anti-angiogenesis benefits of APX3330, and with the increasing implications of inflammatory pathways in diabetic eye disease, there is significant promise for its success in treating diabetic retinopathy, macular edema, and wet age-related macular degeneration.

APX
3330 to be Investigated in the
ZETA-1 Phase 2 Trial in Diabetic Retinopathy

The planned multi-center, randomized, placebo-controlled, double-masked Phase 2 study is designed to evaluate the efficacy of daily oral dosing of APX3330 to improve Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) score in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR). The trial is expected to enroll 100 patients in early 2021 over multiple sites in the US and will evaluate a 600mg daily dosage of APX3330 over the course of 24 weeks. The primary endpoint will be the percentage of patients with a ≥ 2-step improvement in DRSS score in the study eye at week 24. Please refer to ocuphire.com for more information.

About Ocuphire Pharma

Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol^® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s recent Phase 2 clinical trials. For more information, please visit www.ocuphire.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire’s product candidates and potential. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of
various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials; (ii) regulatory requirements or developments; (i
ii
) changes to clinical trial designs and regulatory pathways; (
i
v) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, and (vii) the effects of COVID-19 on clinical programs and business operations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC (including the proxy statement/prospectus included in that certain Registration Statement on Form S-4 (File No. 333-239702) initially filed with the SEC on July 6, 2020 and declared effective by the SEC on October 2, 2020. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Ocuphire Contact:

Mina Sooch, President & CEO
Ocuphire Pharma, Inc.
(248) 681-9815
[email protected]
www.ocuphire.com

Corey Davis, Ph.D.
LifeSci Advisors
[email protected]

–  Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency –

–  Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment of ENPP1 deficiency –

–  Expect to initiate INZ-701 Phase 1/2 clinical trials for ENPP1 and ABCC6 deficiencies in first half of 2021 –

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.

“ENPP1 deficiency is a systemic, progressive and continuous disease occurring over the course of a patient’s lifetime, starting as early as fetal development and spanning into adulthood. The fact that INZ-701 had previously received orphan drug designation and now rare pediatric disease and fast track designations underscores the significant unmet medical need for a treatment for this disease,” said Axel Bolte, MSc, MBA, co-founder, president and chief executive officer of Inozyme Pharma. “I’m pleased with the progress we have made with U.S. and European regulatory authorities, and we remain on track to initiate our planned Phase 1/2 clinical trials in the first half of 2021, subject to clearance of our regulatory applications.”

Recent Business Highlights

• Submitted Clinical Trial Application (CTA) for INZ-701 for the treatment of ENPP1 deficiency – Inozyme recently submitted its first CTA to initiate a Phase 1/2 clinical trial of INZ-701 for the treatment of ENPP1 deficiency to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
• Received Rare Pediatric Disease Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA) for INZ-701 for the treatment of ENPP1 deficiency – The FDA grants rare pediatric disease designation to drugs for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect children aged from birth through 18 years and affect fewer than 200,000 people in the U.S. Under the FDA’s Rare Pediatric Disease Priority Review Voucher program, a sponsor who receives approval of a biologics license application (BLA) for a rare pediatric disease product application may be eligible for a voucher which can be redeemed to obtain priority review for a subsequent marketing application for a different product. Separately, Fast Track Designation facilitates the potential expedited development and review of a drug for the treatment of a serious or life-threatening disease and that has demonstrated the potential to address unmet medical needs. Benefits of this designation include frequent engagements with the FDA to discuss the drug’s clinical development plan, eligibility for priority review, and a rolling review of a BLA. Previously, the FDA and the European Medicines Agency (EMA) had granted orphan drug designation to INZ-701 for the treatment of ENPP1 deficiency.
• Completed disease burden study in ENPP1 deficiency and ABCC6 deficiency – Inozyme and GACI Global, a patient advocacy organization dedicated to bettering the lives of families affected by Generalized Arterial Calcification of Infancy and/or Autosomal Recessive Hypophosphatemic Rickets Type 2 (GACI/ARHR2), completed a study to characterize the burden of disease and understand the systemic progression of disease for the rare genetic diseases of both ENPP1 deficiency and ABCC6 deficiency from the perspective of a patient and/or parent. Inozyme expects to share data from this study in 2021.

Upcoming Anticipated Milestones, Subject to COVID-19 Dynamics

• INZ-701 for ENPP1 deficiency
  • Early 2021: Clearance of IND and CTAs
  • H1 2021: Initiation of Phase 1/2 clinical trial
  • H1 2021: Initiation of prospective natural history study
  • H2 2021: Preliminary safety and biomarker data from Phase 1/2 clinical trial
•  INZ-701 for ABCC6 deficiency
  • Early 2021: Clearance of CTAs
  • H1 2021: Initiation of Phase 1/2 clinical trial
  • H2 2021: Preliminary safety and biomarker data from Phase 1/2 clinical trial

Upcoming Investor Conference

• Piper Sandler 32nd Annual Healthcare Conference, November 30 – December 3, 2020

Third Quarter 2020 Financial Results

• Cash Position and Financial Guidance – Cash, cash equivalents and investments were $171.7 million as of September 30, 2020. Based on its current plans, the Company expects that its existing cash, cash equivalents and investments will be sufficient to enable it to fund its operating expenses and capital expenditure requirements at least into the second half of 2022.
• Research and Development (R&D) Expenses– R&D expenses were $25.2 million for the third quarter ended September 30, 2020, compared to $3.3 million for the same period in 2019. The increase was primarily due to an increase of $17.8 million resulting from the non-recurring, non-cash purchase of in-process research and development intellectual property assets from Alexion in exchange for stock of the Company in July 2020, costs associated with preclinical studies and clinical preparation activities with the Company’s CRO, and growth in the number of R&D employees.
• General and Administrative (G&A) Expenses – G&A expenses were $3.1 million for the third quarter ended September 30, 2020, compared to $1.0 million for the same period in 2019. The increase was primarily due to the growth in the number of G&A employees, an increase in legal fees related to patents, new contracts and operations as a public company, and generally higher fees in areas such as audit, tax and information technology to support the Company’s growth.
• Net Loss – Net loss was $28.1 million, or $1.55 loss per share, for the third quarter ended September 30, 2020, compared to $4.0 million, or $3.38 loss per share, for the same period in 2019.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY), is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation and timing of our future clinical trials, our research and development programs, the availability of preclinical study and clinical trial data, the timing of our regulatory applications and the period over which we believe that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company’s ability to successfully resolve the clinical hold with regard to its planned Phase 1/2 clinical trial of INZ-701 for ENPP1 deficiency; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain and protect intellectual property rights related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Condensed Consolidated Balance Sheet Data
(Unaudited)

(in thousands)

	September 30, 2020				December 31, 2019
Cash, cash equivalents and investments	$	171,709			$	47,132
Total assets		178,993				47,944
Total liabilities		11,077				3,236
Convertible preferred stock		—				77,927
Additional paid-in-capital		247,872				1,428
Accumulated deficit		(79,958	)			(34,652	)
Total stockholders’ equity (deficit)		167,916				(33,219	)

Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)

(in thousands, except share and per share data)

	Three Months Ended September 30,								Nine Months Ended September 30,
	2020				2019				2020				2019
Operating expenses:
Research and development	$	25,174			$	3,317			$	39,457			$	10,941
General and administrative		3,142				1,003				6,313				3,097
Total operating expenses		28,316				4,320				45,770				14,038
Loss from operations		(28,316	)			(4,320	)			(45,770	)			(14,038	)
Other income (expense):
Interest income		64				288				306				892
Other income (expense), net		157				(3	)			158				(34	)
Other income (expense), net		221				285				464				858
Net loss	$	(28,095	)		$	(4,035	)		$	(45,306	)		$	(13,180	)
Other comprehensive (loss) income:
Unrealized (losses) gains on available-for-sale securities		(13	)			(2	)			(5	)			8
Total other comprehensive (loss) income		(13	)			(2	)			(5	)			8
Comprehensive loss	$	(28,108	)		$	(4,037	)		$	(45,311	)		$	(13,172	)
Net loss attributable to common stockholders—basic and diluted	$	(28,095	)		$	(4,035	)		$	(45,306	)		$	(13,180	)
Net loss per share attributable to common stockholders—basic and diluted	$	(1.55	)		$	(3.38	)		$	(6.57	)		$	(11.20	)
Weighted-average common shares outstanding—basic and diluted		18,101,496				1,195,309				6,893,745				1,176,769

Investors:
Brian Luque, Director, Investor Relations
(951) 206-1200
[email protected]

Media:

Alex Van Rees, SmithSolve
(973) 442-1555 ext. 111
[email protected]

SAN JOSE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — OpsRamp, a modern SaaS platform for hybrid infrastructure discovery, monitoring, management, and automation, today announced the launch of a new report: “The Change Agents: How IT Operations Teams Are Driving Enterprise Transformation and Value Creation During Uncertain Times.”

In April 2020, OpsRamp published its Thriving in the New Normal: How IT Operations Leaders Can Deliver Business Value in an Economic Slowdown report to analyze how IT teams were adapting technology priorities, staff hiring, and spending plans in response to the pandemic. As the global health crisis continues, OpsRamp conducted a follow-up survey in October 2020. The new survey is based on responses from 230 IT operations and DevOps executives in the U.S. and U.K. with at least 500 employees and $5 million in annual IT budgets. The survey asked about annual spending plans, cost reduction measures, operational challenges, and investment themes for 2020 and beyond.

Here are the top three insights from the report:

IT is a Strategic Differentiator: In the face of restrictive lockdowns and stay-at-home orders, IT budgets have held up remarkably well as technology becomes a critical ingredient in launching new products and services.

• In the second and third quarters of 2020, 60% of IT leaders significantly or moderately increased their annual technology budgets while only 22% significantly or moderately reduced their IT spending in the last two quarters.
• Meanwhile, 63% of participants reported that Covid-19 led them to accelerate or maintain digital transformation initiatives.

Business Priorities Dictate IT Investments: The leading technology investments in the April 2020 survey were information security and compliance, big data and analytics, and public and multi-cloud infrastructure. These priorities have broadly remained the same in the October survey, but remote work and collaboration have grown in importance.

• What is front and center for IT budgets? The critical priorities for IT leaders include information security and compliance (59%), remote work and collaboration (55%), public and multi-cloud infrastructure (50%), and monitoring and management (42%). The pandemic has made digital touchpoints a critical differentiator for customer interactions while resilient technology infrastructure remains a priority for employees working remotely.
• What performance monitoring tools did IT teams buy in 2020? In 2020, technology leaders focused on the following tools to ensure compelling customer and employee experiences.
  — Artificial intelligence for IT operations (57%) solutions help technology practitioners maintain the uptime, reliability, and performance of technology services with contextual, actionable, and predictive insights.
  — Digital experience monitoring (50%) tools put a clear spotlight on business transactions and customer journeys by surfacing end-user interaction insights for complex enterprise services.
  — Network performance monitoring and diagnostics (50%) tools ensure responsive network infrastructure with instrumentation analytics and visualizations for device, flow, and packet-level data.

IT Cost Management and Hiring During Covid-19: With global IT spending expected to fall by 7.3% in 2020, technology leaders have had to employ creative measures to get the most bang for their bucks. IT teams are looking to hire people who can not only help them stay relevant during the pandemic but also build a proper foundation for growth when the economy eventually recovers in 2021.

• Cost reduction measures. Technology leaders have used self-service tools (60% in October versus 54% in April), embraced open source (51% in October versus 50% in April), and reduced technology suppliers (51% in Octobers versus 59% in April) to save money and rationalize their IT operations portfolios.
• Hiring priorities. Enterprises have either recently hired or are planning to recruit the following team members:
  — Financial managers (54%) who can help IT teams present a compelling business case for technology investments,
  — Senior IT leaders (47%) who can marshal the right resources to successfully execute digital transformation programs, and
  — Cloud operators (44%) who can shift, monitor, and maintain enterprise workloads on public cloud infrastructure.

“I’m not surprised that the majority of companies are pressing ahead with digital transformation projects and increasing spend despite the pandemic,” said Varma Kunaparaju, CEO of OpsRamp. “Organizations that fail to make sound IT investments in this critical phase will lose customer mindshare, fall behind their competition, and slowly become irrelevant in a global economy that is delivering disproportionate returns for digital leaders. What does stand out is the number of companies hiring financial managers to help IT teams justify new technology. Reckless spending on the latest shiny tech toy is being replaced by thoughtful, data-driven decision making, which bodes well for the entire industry.”

The report is available for download here.

About OpsRamp

OpsRamp
is an IT operations management software company whose SaaS platform is used by enterprise IT teams to monitor and manage their cloud and on-premises infrastructure. Key capabilities of the OpsRamp platform include: hybrid infrastructure discovery and monitoring, event and incident management, and remediation and automation, all of which are powered by artificial intelligence. OpsRamp investors include Sapphire Ventures, Morgan Stanley Expansion Capital and HPE.

Visit the OpsRamp Newsroom for all media coverage and press releases.

Visit the OpsRamp Blog.

OpsRamp on Twitter: https://twitter.com/OpsRamp

OpsRamp on LinkedIn: https://www.linkedin.com/company/opsramp

Media contact:

Kevin Wolf

TGPR

(650) 483-1552

[email protected]

Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99349270-dae8-4953-b4ba-5c39a7c830c5

https://www.globenewswire.com/NewsRoom/AttachmentNg/21059407-fa46-47c8-a946-31d815e58dbd

Allows for Increases in Private Label and Direct-to-Consumer

HICKSVILLE, NY, Nov. 12, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a diversified health and wellness company, is pleased to announce the installation of new high-speed equipment to expand production at its Pure Health Products (“PHP”) facility in Lacey, Washington.

The new production line equipment increases capacity by 8,000 units per day and adds speed and efficiency with automated processes. Upgrading from manual to automated equipment for tinctures, salves, cryogels, and massage oils greatly increase the production output by over three hundred percent (300%). The increase in capacity enables the Company to expand its capabilities in private label and direct-to-consumer.

Marco Alfonsi, Can B’s Chief Executive Officer, commented, “We are pleased to announce that phase two of upgrading the manufacturing capacity is nearly complete. The final equipment has been fully tested and installed in our Lacey, Washington facility’s production cleanroom. This upgrade allows Pure Health Products to produce up to 10,000 units a day of bottles, tinctures, salves, lotions, or creams combined. The plant capacity will allow a potential bottling production of $40 million in sales at wholesale price.”

Shanghai Panda Intelligent Machinery Co. was charged with the task of building a custom bottling line, designed by David Posel, Chief Scientist of PHP. The bottling line features two independent main bottling machines that merge into a single shrink-film machine and heat-shrink tunnel. The machines and layout were designed specifically with the needs of producing the CBD industry’s core retail products in mind. This custom triple bottling line with unified shrink tunnel will fill, cap, label, and shrink band all products including droppers, sprays, salves, lotions, creams, capsules, and cryogels. The main tincture and spray bottling line and the bottling line that fills the larger lotions, salves, and creams are now fully operational and on-line.

The new Capsule Pouch Packing Machine was custom configured and manufactured by Ming Yue Packaging Machinery Co. to allow PHP to produce single-use packs of their popular capsule recipes, and custom or white-label products from 1 capsule to 12 capsules in each 3×3 inch retail pouch. This machine features a custom configured dual capsule feeding system, which allows two independently controlled precision capsule feeders to deposit into the same retail pouch. This uniquely allows PHP to produce any configuration of two different capsule blends in the same unit with up to 12 total capsules.

This concept gives PHP the leading edge in first-to-market packaging as no competitor has utilized this method to-date. The lot and expiration numbers are heat-stamped onto the edge of each packet to ensure proper consumer quality standards. This custom dual-feed packaging machine is rated to produce up to 10,000 packets per day.

About Can B Corp.

Can B Corp. (OTCQB: CANB) is a Health & Wellness company providing the highest quality cannabidiol (CBD) products under the brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil, and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B is also an exclusive partner of the LifeGuard® Brand in developing a line of consumer products. The Company is also launching Super Foods, a line of nutritional supplements. Can B Corp. owns and operates an R&D and production facility in Lacey, WA, and Green Grow Farms, a licensed hemp grow and cultivation in New York. To learn more about Can B Corp. and our comprehensive line of high-quality CBD products, please visit: Canbiola.com and www.CanBCorp.com, follow Can B Corp on Instagram and Facebook, or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: CanBCorp.com

Twitter @CanBCorp

Instagram @canbcorp

Facebook @ Can B Corp

Forward-Looking Statements

Forward-looking statements and risks and uncertainties discussed in this release contain forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape, or manner of our future financial condition or stock price. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Investors and Media:

[email protected]

(917) 658-7878

Seoul, South Korea, Nov. 12, 2020 (GLOBE NEWSWIRE) — GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of online and mobile games, today announced that Ragnarok X: Next Generation has been ranked as the first in top grossing of Google Play in Taiwan and Hong Kong followed by Apple App Store.  

As the No.1 title in top grossing of Google Play hasn’t changed easily, it shows the popularity of the game in Taiwan and Hong Kong has been growing rapidly.

Gravity said, ” In return for this heated local users’ support, we are doing our best with ByteDance Ltd., our publisher of Ragnarok X: Next Generation. We will try to make this game to be loved for a long term through interactive communications with more users.

ByteDance Ltd., a global IT company, publishes this game and Gravity Communications Co., Ltd., Gravity’s subsidiary in Taiwan, supports the ByteDance as a joint publisher.

[Ragnarok X: Next Generation Official Website] https://rox.gnjoy.com.tw/

 [Ragnarok X: Next Generation _Facebook Page] https://www.facebook.com/ROXNextGeneration

About GRAVITY Co., Ltd. —————————————————

Gravity is a developer and publisher of online and mobile games. Gravity’s principal product, Ragnarok Online, is a popular online game in many markets, including Japan and Taiwan, and is currently commercially offered in 93 markets and countries. For more information about Gravity, please visit http://www.gravity.co.kr.

Contact:

Mr. Heung Gon Kim
Chief Financial Officer
Gravity Co., Ltd.
Email: [email protected]

Ms. Jin Lee
Ms. Hye Ji An
IR Unit
Gravity Co., Ltd.
Email: [email protected]
Telephone: +82-2-2132-7800~1

– Investment
demonstrates DENSO’s commitment to corporate venture strategy, even in
challenging
times,
and supports company’s
push into new mobility areas
–

SOUTHFIELD, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) — DENSO, a leading mobility supplier, today announced it has invested in Lambda:4, a German company that develops wireless positioning technologies for short-range applications using Bluetooth Low Energy. The investment will strengthen DENSO’s passive digital key, increasing its location accuracy and user authentication capabilities. This improves safety and security for those using the key on smart devices to enter a vehicle.

Passive digital keys allow approved users to connect their smart devices, such as smart phones, to vehicles without the user ever having to touch a button or open an app. Through the passive digital key, a car can identify when an approved user is approaching; when the approved user is at the car door, unlocking it; and when the approved user is inside, enabling ignition. For this sequence to progress seamlessly, it is critical for the vehicle to be able to quickly identify and authenticate an approved user and pinpoint their location in and around the car.

Lambda:4’s expertise, perfected in producing localization systems for avalanche search and rescue missions, will rapidly increase DENSO’s innovation in localization systems.

“As much of society goes digital, we are building a connected ecosystem that bridges the gap between consumer and automotive technologies,” said Ron Schubert, director of Body Electronics Systems at DENSO. “We believe that personalized passive access to vehicles, owned by individuals or deployed in shared fleets, will help make road travel more convenient, secure and enjoyable for commuters.”

The investment is the latest development in DENSO’s work with passive digital keys, which goes back to 2012, when it began developing the technology. Since then, DENSO has become a leader in the space, continually advancing the micro-locating performance of its solution. In 2017, the company acquired InfiniteKey, further expanding the key’s functionality. DENSO’s integrated key is now on the road today.

“Our goal at DENSO is to create products and technologies that enhance mobility and meet our partners’ needs, helping them deliver seamless and user-friendly experiences to their customers,” said Tony Cannestra, director of Corporate Ventures at DENSO. “We are pleased to forge ahead with this investment not only despite the coronavirus pandemic, but because it will help us develop safer transportation solutions during it. We continue to focus on new mobility areas and potential partners, particularly in connectivity and autonomy, who can help us address transportation needs of today and beyond.”

A pioneer in phase-based ranging technology, Lambda:4 has accrued more than 15 years of experience and patents in ranging and positioning technologies used in complex multi-pathing environments. Now, as a leader in core positioning system technology and intellectual property, the company is poised to capitalize on the expanding need for location-aware solutions.

“Digitizing the world is an ongoing trend. By using standard Bluetooth chipsets, our technology offers a low-cost, universal way to enable location aware applications, like passive access and digital keys,” said Rönne Reimann, CEO of Lambda:4. “We are thrilled to have DENSO at our side to share the same vision about a world with seamless access – be it your car, a hotel or your home.” 

As part of the company’s Second Founding, DENSO is committed to boosting its research and development efforts by expanding into new mobility areas where it sees opportunities to make transportation more efficient, safer and sustainable for all.

About DENSO

DENSO is a $47.6 billion global mobility supplier that develops advanced technology and components for nearly every vehicle make and model on the road today. With manufacturing at its core, DENSO invests in its 200 facilities to produce thermal, powertrain, mobility, electrification, & electronic systems, to create jobs that directly change how the world moves. The company’s 170,000+ employees are paving the way to a mobility future that improves lives, eliminates traffic accidents, and preserves the environment. Globally headquartered in Kariya, Japan, DENSO spent 9.9 percent of its global consolidated sales on research and development in the fiscal year ending March 31, 2020. For more information about global DENSO, visit https://www.denso.com/global.

In North America, DENSO is headquartered in Southfield, Michigan, and employs 27,000+ engineers, researchers and skilled workers across 51 sites in the U.S, Canada and Mexico. In the United States alone, DENSO employs 17,700+ employees across 14 states (and the District of Columbia) and 41 sites. In fiscal year ending March 31, 2020, DENSO in North America generated $10.9 billion in consolidated sales. DENSO is committed to advancing diversity and inclusion inside the company and beyond – a principle that brings unique perspectives together, bolsters innovation and pushes DENSO forward. Join us, and craft not only how the world moves, but also your career: densocareers.com. For more information, go to https://www.denso.com/us-ca/en/.

About Lambda
:4

Lambda:4 was founded in Hamburg, Germany. With a team of 13 employees including veterans from the automotive and wireless connectivity industry, Lambda:4 is focused on providing the most accurate, robust and secure wireless ranging technology. Over the last years Lambda:4 developed many patents and prototypes concentrating on keyless entry systems. Lambda:4 develops low level routines to optimize chipsets for use with their technology and embedded high level algorithms to calculate the range or a position. For more information, go to http://www.lambda4.com/en/

Contact:
Andrew Rickerman

DENSO International America, Inc.
(734) 560-8752
[email protected]